Literature DB >> 30559590

A Bitter Pill to Swallow: Why Medication Safety Is Critical in Hepatitis C Treatment.

Karyn M Sullivan, Linda M Spooner, Emily Harris, Kenneth Lowe, George M Abraham.   

Abstract

PURPOSE: To provide medication safety tips to optimize the management of patients receiving treatment for chronic hepatitis C virus (HCV) infection.
SUMMARY: Ensuring safe medication use in patients who receive treatment for HCV infection is a crucial component in providing optimal patient care. Because of the complexity of available treatment options, numerous challenges exist in preventing medication errors with HCV therapies. This article will focus on the selection of appropriate treatment options along with proper dosing and duration, awareness of concomitant disease states and drug interactions, identifying adverse drug reactions (ADRs) and patient counseling points, the provision of adherence counseling and prevention of treatment interruptions, improving communication with patients and between pharmacies, and recognizing the importance of a multidisciplinary approach.
CONCLUSION: Maintaining awareness of medication safety strategies geared toward HCV pharmacotherapy is critical for providing optimal care for patients while minimizing the opportunity for errors.

Entities:  

Keywords:  hepatitis C virus (HCV); medication errors; medication safety

Year:  2018        PMID: 30559590      PMCID: PMC6281151     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  11 in total

1.  Optimizing workflow at a multidisciplinary clinic for management of hepatitis C virus infection.

Authors:  Megan Grischeau; Jane Zenner
Journal:  Am J Health Syst Pharm       Date:  2012-12-15       Impact factor: 2.637

2.  Impact of specialty pharmacy on telaprevir-containing 3-drug hepatitis C regimen persistence.

Authors:  Rochelle R Henderson; Jay Visaria; Gail G Bridges; Mary Dorholt; Rebecca J Levin; Sharon Glave Frazee
Journal:  J Manag Care Spec Pharm       Date:  2014-12

3.  Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy.

Authors:  Rima A Mohammad; Marilyn N Bulloch; Juliana Chan; Paulina Deming; Bryan Love; Lisa Smith; Betty J Dong
Journal:  Pharmacotherapy       Date:  2014-10-31       Impact factor: 4.705

4.  Physical, social, and psychological consequences of treatment for hepatitis C : a community-based evaluation of patient-reported outcomes.

Authors:  M Michele Manos; Chanda K Ho; Rosemary C Murphy; Valentina A Shvachko
Journal:  Patient       Date:  2013       Impact factor: 3.883

5.  A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.

Authors:  José Antonio Carrión; Elena Gonzalez-Colominas; Montserrat García-Retortillo; Nuria Cañete; Isabel Cirera; Susanna Coll; Maria Dolors Giménez; Carmen Márquez; Victoria Martin-Escudero; Pere Castellví; Ricard Navinés; Juan Ramon Castaño; Josep Anton Galeras; Esther Salas; Felipe Bory; Rocío Martín-Santos; Ricard Solà
Journal:  J Hepatol       Date:  2013-06-26       Impact factor: 25.083

6.  Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers.

Authors:  Donna M Evon; Carol E Golin; Jason E Bonner; Catherine Grodensky; Jennifer Velloza
Journal:  J Clin Gastroenterol       Date:  2015 May-Jun       Impact factor: 3.062

Review 7.  Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Paulina Deming; Michelle T Martin; Juliana Chan; Thomas J Dilworth; Rania El-Lababidi; Bryan L Love; Rima A Mohammad; Amy Nguyen; Linda M Spooner; Suzanne B Wortman
Journal:  Pharmacotherapy       Date:  2016-02-05       Impact factor: 4.705

8.  Increasing Access to Hepatitis C Virus Medications: A Program Model Using Patient Navigators and Specialty Pharmacy to Obtain Prior Authorization Approval.

Authors:  Trang M Vu; Wilma Toribio; Farah Riazi; Genesis Ciprian; Nathalia Gibbs; Martha Giardina; Jocelyn A Camacho; Korin Parrella; Joy Cambe; Catherine Amory; Rachel Chasan; Keith M Sigel; Jeffrey J Weiss
Journal:  J Manag Care Spec Pharm       Date:  2018-04

9.  Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection.

Authors:  Ruian Ke; Claude Loverdo; Hangfei Qi; Ren Sun; James O Lloyd-Smith
Journal:  PLoS Comput Biol       Date:  2015-06-30       Impact factor: 4.475

10.  Chronic hepatitis C virus (HCV) disease burden and cost in the United States.

Authors:  Homie Razavi; Antoine C Elkhoury; Elamin Elbasha; Chris Estes; Ken Pasini; Thierry Poynard; Ritesh Kumar
Journal:  Hepatology       Date:  2013-05-06       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.